# Clinical trials recruiting in Moldova: 60 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 60 trials recruiting or not yet recruiting with a site in Moldova, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Moldova: 60 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/country/moldova

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 60
- Recruiting or not yet: 60
- Read on: November 19, 2026

## Trials

The 25 newest of 60, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 21, 2026 | NCT07885891 | Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia | Wockhardt | Phase 3 | Not yet recruiting | Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP) | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885891) |
| September 3, 2026 | NCT07801222 | A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft... | SOTIO Biotech a.s. | Phase 1/2 | Not yet recruiting | Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS), Osteosarcoma, Advanced | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801222) |
| August 13, 2026 | NCT07762027 | A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection | Assembly Biosciences | Phase 2 | Not yet recruiting | Chronic Hepatitis D Infection | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762027) |
| August 12, 2026 | NCT07760831 | A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Moderate to Severe Ulcerative Colitis | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760831) |
| July 21, 2026 | NCT07717671 | VIPPSTAR-G1 Digital Early Intervention for Visual Impairment | Università degli Studi di Brescia | Not applicable | Not yet recruiting | Visual Impairment, Cerebral Visual Impairment, Neurodevelopmental Disorders, Prematurity | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717671) |
| July 9, 2026 | NCT07693751 | A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer | SOTIO Biotech a.s. | Phase 1/2 | Recruiting | Colorectal Cancer (Locally Advanced or Metastatic) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07693751) |
| July 6, 2026 | NCT07684820 | To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment | Expedition Therapeutics, Inc | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684820) |
| April 23, 2026 | NCT07547540 | A Study of LY3971297 in Participants With Heart Failure | Eli Lilly and Company | Phase 1 | Recruiting | Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07547540) |
| April 16, 2026 | NCT07533955 | A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis | Jade Biosciences, Inc. | Phase 1 | Recruiting | Rhematoid Arthritis | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07533955) |
| March 17, 2026 | NCT07476326 | Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma | Biocon Biologics UK PLC | Phase 1 | Recruiting | Melanoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476326) |
| March 16, 2026 | NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and... | Boehringer Ingelheim | Phase 3 | Recruiting | Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 670 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472517) |
| March 16, 2026 | NCT07472491 | A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients | GE Healthcare | Phase 2/3 | Recruiting | Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion | 640 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472491) |
| March 3, 2026 | NCT07444931 | Validation of Sudden Cardiac Arrest Risk Factors in Patients With CAD | Tampere Heart Hospital | Observational | Recruiting | Coronary Arterial Disease (CAD), Sudden Cardiac Arrest, Sudden Cardiac Death | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444931) |
| February 25, 2026 | NCT07433335 | A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis | SciRhom GmbH | Phase 1 | Recruiting | Rheumatoid Arthritis | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07433335) |
| February 5, 2026 | NCT07389044 | A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | IntegerBio | Phase 1 | Recruiting | Chronic Hepatitis B Virus Infection | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07389044) |
| January 28, 2026 | NCT07374471 | A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Ulcerative Colitis (UC) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07374471) |
| January 23, 2026 | NCT07363590 | A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) | Merck Sharp & Dohme LLC | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07363590) |
| December 22, 2025 | NCT07296315 | Confirmatory Clinical Study in Active Ulcerative Colitis | MRM Health NV | Phase 2 | Recruiting | Colitis, Ulcerative | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07296315) |
| November 21, 2025 | NCT07240571 | Randomized Controlled Trial of a Family-focused Intervention for Caregivers and Young Adolescents (Phase 3 of FLOURISH) | University of Klagenfurt | Not applicable | Recruiting | Adolescent - Emotional Problem, Parent Child Relationship, Family Functioning, Well-Being, Psychological | 1,280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07240571) |
| November 17, 2025 | NCT07230353 | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis | Xencor, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230353) |
| November 3, 2025 | NCT07223658 | Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia | Arrowhead Pharmaceuticals | Phase 1/2 | Recruiting | Hyperlipidemia; Mixed | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223658) |
| October 9, 2025 | NCT07213778 | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Symptomatic Venous Thromboembolism (VTE) | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213778) |
| October 7, 2025 | NCT07209761 | A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Recruiting | Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis | 532 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07209761) |
| October 6, 2025 | NCT07207954 | Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | Lifordi Immunotherapeutics, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07207954) |
| September 22, 2025 | NCT07185009 | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative... | Sanofi | Phase 3 | Recruiting | Ulcerative Colitis | 751 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07185009) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| The Institute of Oncology, Arensia Exploratory Medicine | Chisinau | 3 |
| Arensia Exploratory Medicine Research Unit, Institute of Oncology | Chisinau | 2 |
| "Sfanta Treime" Municipal Clinical Hospital | Chisinau | 2 |
| Institute of Oncology, ARENSIA Exploratory Medicine | Chisinau | 2 |
| IMSP Institutul de Ftiziopneumologie Chiril Draganiuc - Phthisiopneumology | Chisinau | 1 |
| Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E.M. | Chisinau | 1 |
| Institutul de Neurologie si Neurochirurgie | Chisinau | 1 |
| IMSP Republican Clinical Hospital "Timofei Mosneaga", Clinical Trial Unit ARENSIA EXPLORATORY MEDICINE | Chisinau | 1 |
| PMSI "Timofei Mosneaga" Republican Clinical Hospital, Outpatient Department | Chisinau | 1 |
| PMSI "Timofei Mosneaga" Republican Clinical Hospital, Therapy Department, Division of Gastroenterology | Chisinau | 1 |
| Rtl Sm Srl | Chisinau | 1 |
| PMSI Institute of Pneumology "Chiril Draganiuc" | Chisinau | 1 |
| ARENSIA Research Clinic | Chisinau | 1 |
| PMSI Republican Clinical Hospital "Timofei Mosneaga", Arensia Exploratory Medicine Phase I Unit | Chisinau | 1 |
| PMSI 'Timofei Mosneaga' Republican Clinical Hospital | Chisinau | 1 |
| 'Sfanta Treime' Municipal Clinical Hospital | Chisinau | 1 |
| ARENSIA Exploratory Medicine at Republican Clinical Hospital | Chisinau | 1 |
| National Institute of Oncology, Arensia Research Clinic | Chisinau | 1 |
| PMSI Emergency Medicine Institute | Chisinau | 1 |
| IMSP Spitalul Clinic Municipal "Sfanta Treime" | Chisinau | 1 |
| Arensia Exploratory Medicine Moldova | Chisinau | 1 |
| Gheorghe Paladi Municipal Hospital | Chisinau | 1 |
| ARENSIA Exploratory Medicine | Chisinau | 1 |
| Instituția Medico-Sanitară Publică "Institutul de Cardiologie" | Chisinau | 1 |
| Arensia Exploratory Medicine Moldova - IMSP Institutul Oncologic. Strada Nicolae Testemitanu Nr 30 | Chisinau | 1 |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 17 |
| Phase 1/2 | 14 |
| Phase 2 | 11 |
| Phase 2/3 | 1 |
| Phase 3 | 10 |
| Not applicable | 3 |
| Observational | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Colitis, Ulcerative | 8 |
| Inflammatory Bowel Diseases | 5 |
| Arthritis, Rheumatoid | 5 |
| Crohn Disease | 4 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Hepatitis B, Chronic | 3 |
| Lymphoma, B-Cell, Marginal Zone | 3 |
| Lymphoma, Follicular | 3 |
| Waldenstrom Macroglobulinemia | 3 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 |
| Lymphoma, Mantle-Cell | 3 |
| Tuberculosis, Multidrug-Resistant | 2 |
| Obesity | 2 |
| Breast Neoplasms | 2 |
| Lymphoma, Non-Hodgkin | 2 |
| Lupus Erythematosus, Systemic | 2 |
| Colitis | 1 |
| Sarcoma | 1 |
| Osteosarcoma | 1 |
| Hyperlipoproteinemia Type II | 1 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 |
| Acquired Immunodeficiency Syndrome | 1 |
| Tuberculosis, Pulmonary | 1 |
| Overweight | 1 |
| Colorectal Neoplasms | 1 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 4 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 3 |
| [Xencor, Inc.](https://specstream.ai/data/clinical-trials/company/xencor-inc) | 2 |
| SOTIO Biotech a.s. | 2 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 2 |
| [Otsuka Pharmaceutical Development & Commercialization, Inc.](https://specstream.ai/data/clinical-trials/company/otsuka-pharmaceutical-development-and-commercialization-inc) | 1 |
| Spyre Therapeutics, Inc. | 1 |
| Lifordi Immunotherapeutics, Inc. | 1 |
| [Arrowhead Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/arrowhead-pharmaceuticals) | 1 |
| [argenx](https://specstream.ai/data/clinical-trials/company/argenx) | 1 |
| Yale University | 1 |
| Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 1 |
| University College, London | 1 |
| Wave Life Sciences USA, Inc. | 1 |
| Mirador Therapeutics, Inc. | 1 |
| Tune Therapeutics, Inc. | 1 |
| Biocon Biologics UK PLC | 1 |
| Expedition Therapeutics, Inc | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| SynAct Pharma Aps | 1 |
| Arbutus Biopharma Corporation | 1 |
| University Medicine Greifswald | 1 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cocktail bars in the United States](https://specstream.ai/data/businesses/cocktail-bars/united-states)
- [Australian restaurants in the United States](https://specstream.ai/data/businesses/australian-restaurants/united-states)
- [Tax preparation firms in the United States](https://specstream.ai/data/businesses/tax-preparation-firms/united-states)
- [Plumbers in the United States](https://specstream.ai/data/businesses/plumbers/united-states)
- [Lawn care companies in the United States](https://specstream.ai/data/businesses/lawn-care-companies/united-states)
- [Fmcg wholesalers in the United States](https://specstream.ai/data/businesses/fmcg-wholesalers/united-states)
